Latest Research And Development News

Spectur Limited reported a solid quarter ending June 2025, posting positive net operating cash flow and increasing its cash reserves to over $1 million. The company maintained steady financing arrangements while managing operating costs effectively.

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

Biotron Limited has successfully raised $1.27 million through an entitlement issue to fund its antiviral drug development, including a promising Hepatitis B compound that cleared its initial animal safety study.

Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.

Radiopharm Theranostics reports significant progress in its oncology radiopharmaceutical pipeline, including FDA Fast Track designation and dose escalation approvals, supported by a solid cash runway through mid-2026.

Iondrive Limited advances its proprietary battery recycling technology with a pilot plant design, European consortium formation, and new e-waste initiatives, supported by significant grant funding.

Biome Australia Limited has delivered record sales revenue in Q4 FY25 alongside positive EBITDA, setting the stage for its first full-year net profit. Strategic product launches and international expansion underpin its strong growth trajectory.

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.

Advanced Braking Technology Ltd (ABT) posted a robust FY25 with sales up 27% and underlying profits nearly doubling, driven by strong international demand and innovation milestones.

BCI Minerals reports solid progress on its Mardie Salt Operation with 69% construction complete and commissioning of the first crystallisers, advancing towards first salt shipment by late 2026.

Anatara Lifesciences has received nearly $1 million from the Australian Government’s R&D tax incentive, providing a vital capital injection to advance its Anti-Obesity pre-clinical studies.

Noxopharm Limited has successfully completed the first low-dose cohort in its HERACLES clinical trial for SOF-SKN™, clearing the way for higher dose testing in autoimmune disease treatment.